Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely
S Chevaliez, C Hézode, S Bahrami, M Grare… - Journal of …, 2013 - Elsevier
Background & Aims Information regarding long-term HBsAg kinetics during treatment with
nucleoside/nucleotide analogues is limited. The aim of the present study was to assess
whether finite nucleoside/nucleotide analogue treatment duration could be envisaged
during the patient's lifetime. Methods Patients with chronic hepatitis B receiving different
schedules of nucleoside/nucleotide analogues were followed for a median duration of 102
months, ie, 8.5 years (interquartile range: 88–119 months). Long-term HBV DNA and HBsAg …
nucleoside/nucleotide analogues is limited. The aim of the present study was to assess
whether finite nucleoside/nucleotide analogue treatment duration could be envisaged
during the patient's lifetime. Methods Patients with chronic hepatitis B receiving different
schedules of nucleoside/nucleotide analogues were followed for a median duration of 102
months, ie, 8.5 years (interquartile range: 88–119 months). Long-term HBV DNA and HBsAg …
